Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

OncoProTools Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and treatment.

Coordinator
Universiteit Antwerpen, Belgium
Runs
1 September 2022 to 31 August 2026
Status
Running
EU funding
€2.3m
Total cost
—
Partners
22 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101073231

What the project is doing

In the project's own words, from its summary on CORDIS.

Europe has a high cancer burden: in 2020, 2.7 million EU citizens were diagnosed with the disease and 1.3 million lost their lives to it. This toll is expected to increase further, mainly because Europe's population is ageing: by 2035, cancer will be the leading cause of death in the EU. In 2021, the EC published its ‘Europe's Beating Cancer Plan’ (EBCP), calling for a big push in cancer research. Cancer diagnostics and therapeutics should rapidly become more effective and selective, patient-friendly and personalized.

All these goals are directly addressed by developing better tumor targeting strategies. Typically, they consist of equipping diagnostics and therapeutics with a vector unit. The vector unit binds to a protein that is overexpressed on cancer cells or in the Tumor Micro-Environment (TME), causing the diagnostic or therapeutic payload to accumulate in the tumor. Over the last decades, huge effort has gone in approaches that use antibodies as vectors, but return-on-investment has overall been rather poor.

Exciting, recent innovations rely on small molecule vectors that target TME proteases. Proteases are ideal candidates for tumor targeting: they are often strongly overexpressed in the TME and possess an active site that allows high-affinity anchoring of vectors. Members of this consortium have played a leading role in these developments. OncoProTools wants to force breakthroughs in cancer diagnosis and therapy by:1) Exploring innovative venues for protease targeting in CAR T cell therapy. 2) Discovering novel vectors that bind to other TME proteases: cathepsins S, B, L and granzyme B3) Personalize applications of protease targeting: deliver innovative diagnostics through deeper understanding of TME biology.

At the same time, OncoProTools will deliver a training program that truly captures the MSCA values, to 10 Doctoral Candidates. They will be provided with all capabilities to become leaders of tomorrow's R&I in Europe.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit AntwerpenAntwerpenBelgiumCoordinator
Cancer Patients EuropeBruxelles / BrusselBelgiumAssociatedpartner
European Cancer Patient CoalitionBruxelles / BrusselBelgiumAssociatedpartner
Fox Biosystems NVDiepenbeekBelgiumAssociatedpartner
HistoGeneX N.V.BerchemBelgiumAssociatedpartner
Quintessence ConsultingEdegemBelgiumAssociatedpartner
Vixen Biosystems BVAntwerpenBelgiumAssociatedpartner
Insel Gruppe AGBernSwitzerlandAssociatedpartner
Universitaet BernBernSwitzerlandAssociatedpartner
Helmholtz-Zentrum Dresden-Rossendorf eVDresdenGermanyParticipant
Johannes Gutenberg-Universitat MainzMainzGermanyParticipant
SCV GmbHBerlinGermanyAssociatedpartner
Technische Universitaet DresdenDresdenGermanyAssociatedpartner
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Universidad Autonoma De MadridMadridSpainAssociatedpartner
Cromed Kutato Es Szolgaltato Kozpontok KftBudapestHungaryParticipant
Semmelweis EgyetemBudapestHungaryAssociatedpartner
Alma Mater Studiorum - Universita Di BolognaBolognaItalyAssociatedpartner
Cellply SRLBolognaItalyParticipant
Dehne MatthiasAmsterdamNetherlandsAssociatedpartner
Faculdade de Farmácia da Universidade de LisboaLisboaPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI